MultiValent Biotherapies
PrivateLast Round
Series A
Jun 16, 2026
Total Funding Raised
$27.43M
Momentum
Top 5%
of companies Caplight tracks
Company Overview
MultiValent Biotherapies operates in Healthcare & Life Sciences and is based in Los Altos, California. Its latest recorded funding round was a Series A round in June 2026.
MultiValent Biotherapies, Inc. is a biotechnology company developing targeted drug conjugate therapies for cancer.
Sector
Healthcare & Life Sciences
Verticals
Biotechnology, Drug Discovery, Clinical Trials, Precision Medicine
Business Model
B2B
Customer Profile
Services & Consulting
AI Layer
Non-AI
Historical Pricing
Historical view of private secondary pricing and transaction trends.
MultiValent Biotherapies Comparables
Compare MultiValent Biotherapies with similar companies based on industry and business-model similarity.
| Company | Similarity | Market Cap |
|---|---|---|
| Coherent Biopharma | 83% | |
| Tianjin Conjustar Biotechnology Co., Ltd. | 78% | |
| Eli Lilly and Company | 77% |
For institutional investors. Book with your work email.
MultiValent Biotherapies Funding Rounds
Historical fundraising activity
For institutional investors. Book with your work email.
Market signals
Structured signals derived from secondary market and firmographic data.
- Jun 16, 2026
$27M round led by Coherent Biopharma
For institutional investors. Book with your work email.
MultiValent Biotherapies Filings
Explore SEC and related filing metadata, where available.
| Type | Date | Amount Offered | Amount Sold | Filing | Pages | Download |
|---|
Filing documents are not displayed on this public page. Request access to learn about available coverage.
Book a demoFor institutional investors. Book with your work email.
Frequently Asked Questions
Common questions about MultiValent Biotherapies's valuation, stock price, and market status.
Is MultiValent Biotherapies a public or private company?
MultiValent Biotherapies is a private company.
What is the current stock price of MultiValent Biotherapies?
MultiValent Biotherapies is a private company, so its shares have no public market price. Caplight tracks MultiValent Biotherapies's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.
How much is MultiValent Biotherapies worth (valuation)?
Valuation information for MultiValent Biotherapies is not publicly available.
Can I buy MultiValent Biotherapies stock?
MultiValent Biotherapies shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.
When was MultiValent Biotherapies's last funding round?
MultiValent Biotherapies's most recent funding round was Series A on June 16, 2026.
Who are the main investors in MultiValent Biotherapies?
Investor information for MultiValent Biotherapies is not publicly disclosed.
Will MultiValent Biotherapies IPO soon?
No public IPO plans have been announced for MultiValent Biotherapies.
How can I track MultiValent Biotherapies secondary market activity?
Caplight tracks bids, offers, and trades in MultiValent Biotherapies's shares on secondary markets.